COST-EFFECTIVENESS ANALYSIS OF ADDING TUMOR TREATING FIELDS THERAPY TO TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ONLY IN PATIENTS WITH GLIOBLASTOMA IN FRANCE

被引：0
|
作者：
Guzman, Nino de Rivera J. [1 ]
Borgel, J. [2 ]
Chavez, G. [3 ]
Puc, C. [2 ]
Indukuri, N. [3 ]
Koh, C. Y. C. [4 ]
Poignant, P. [5 ]
Duteil, E. [5 ]
Gerves-Pinquie, C. [6 ]
Leproust, S. [5 ]
机构：
[1] Novocure Glendale, Glendale, CO USA
[2] Novocure, Paris, France
[3] Novocure Inc, Brentwood, TN USA
[4] Novocure Inc, Portsmouth, NH USA
[5] IQVIA, Paris, France
[6] IQVIA, La Def, France
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE363
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [1] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, Gregory
    Wang, Bruce C. M.
    Pollom, Erqi
    Stieber, Volker W.
    Garrison, Lou
    NEURO-ONCOLOGY, 2018, 20 : 116 - 117
  • [2] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, G. F.
    Wang, B. C. M.
    Pollom, E. L.
    Stieber, V. W.
    Kinzel, A.
    Proescholdt, C.
    Garrison, L.
    NEURO-ONCOLOGY, 2018, 20 : 254 - 254
  • [3] Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
    Guzauskas, Gregory F.
    Pollom, Erqi L.
    Stieber, Volker W.
    Wang, Bruce C. M.
    Garrison, Louis P., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 1006 - 1013
  • [4] Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
    Martin Connock
    Peter Auguste
    Claude Dussart
    Jacques Guyotat
    Xavier Armoiry
    Journal of Neuro-Oncology, 2019, 143 : 605 - 611
  • [5] Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
    Connock, Martin
    Auguste, Peter
    Dussart, Claude
    Guyotat, Jacques
    Armoiry, Xavier
    JOURNAL OF NEURO-ONCOLOGY, 2019, 143 (03) : 605 - 611
  • [6] Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
    Chen, Zhaoyan
    Zhan, Mei
    Tian, Fangyuan
    Xu, Ting
    ONCOLOGY LETTERS, 2020, 19 (01) : 424 - 430
  • [7] The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma
    Bernard-Arnoux, F.
    Lamure, M.
    Ducray, F.
    Aulagner, G.
    Honnorat, J.
    Armoiry, X.
    NEURO-ONCOLOGY, 2016, 18 (08) : 1129 - 1136
  • [8] Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis
    Guzauskas, Gregory F.
    Pollom, Erqi L.
    Stieber, Volker W.
    Wang, Bruce C.
    Garrison, Lou
    CANCER RESEARCH, 2018, 78 (13)
  • [9] Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
    Fishman, Hila
    Monin, Roni
    Dor-On, Eyal
    Kinzel, Adrian
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) : 83 - 94
  • [10] Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
    Hila Fishman
    Roni Monin
    Eyal Dor-On
    Adrian Kinzel
    Adi Haber
    Moshe Giladi
    Uri Weinberg
    Yoram Palti
    Journal of Neuro-Oncology, 2023, 163 : 83 - 94
12345